Drugs / [161Tb]Tb-PSMA-I&T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05521412 | Sep 2022 → Aug 2025 overdue | castration-resistant prostate carcinoma | Peter MacCallum Cancer Centre, Australia | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [(161)Tb]Tb-PSMA-I&T | “First-in-human results of terbium-161 [(161)Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a...” PMID 40617237 ↗ Jul 20251“We aimed to evaluate the safety of [161Tb]Tb-PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC).” PMID 40617237 ↗ Jul 2025 |
| Route | Intravenous | “Up to six cycles of [161Tb]Tb-PSMA-I&T were administered intravenously every 6 weeks” PMID 40617237 ↗ Jul 2025 |